1088 related articles for article (PubMed ID: 8929245)
1. Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
Ikegami Y; Yano S; Nakao K; Fujita F; Fujita M; Sakamoto Y; Murata N; Isowa K
Arzneimittelforschung; 1995 Nov; 45(11):1225-30. PubMed ID: 8929245
[TBL] [Abstract][Full Text] [Related]
2. Effects of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells.
Ikegami Y; Yano S; Nakao K
Arzneimittelforschung; 1996 Feb; 46(2):201-4. PubMed ID: 8720314
[TBL] [Abstract][Full Text] [Related]
3. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models.
Akinaga S; Gomi K; Morimoto M; Tamaoki T; Okabe M
Cancer Res; 1991 Sep; 51(18):4888-92. PubMed ID: 1893379
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Killion JJ; Beltran P; O'Brian CA; Yoon SS; Fan D; Wilson MR; Fidler IJ
Oncol Res; 1995; 7(9):453-9. PubMed ID: 8835289
[TBL] [Abstract][Full Text] [Related]
7. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
Geiger T; Müller M; Dean NM; Fabbro D
Anticancer Drug Des; 1998 Jan; 13(1):35-45. PubMed ID: 9474241
[TBL] [Abstract][Full Text] [Related]
9. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
Andrejauskas-Buchdunger E; Regenass U
Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.
Ikegami Y; Yano S; Nakao K
Jpn J Pharmacol; 1996 Jan; 70(1):65-72. PubMed ID: 8822090
[TBL] [Abstract][Full Text] [Related]
12. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
[TBL] [Abstract][Full Text] [Related]
13. A selective protein kinase C inhibitor (CGP 41251) positively and negatively modulates melanoma cell MSH receptors.
Siegrist W; Sauter P; Eberle AN
J Recept Signal Transduct Res; 1995; 15(1-4):283-96. PubMed ID: 8903945
[TBL] [Abstract][Full Text] [Related]
14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
15. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice.
Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Anticancer Res; 2003; 23(2B):1395-9. PubMed ID: 12820400
[TBL] [Abstract][Full Text] [Related]
16. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
Meyer T; Regenass U; Fabbro D; Alteri E; Rösel J; Müller M; Caravatti G; Matter A
Int J Cancer; 1989 May; 43(5):851-6. PubMed ID: 2714889
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.
Akinaga S; Nomura K; Gomi K; Okabe M
Cancer Chemother Pharmacol; 1993; 32(3):183-9. PubMed ID: 8500222
[TBL] [Abstract][Full Text] [Related]
18. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
[TBL] [Abstract][Full Text] [Related]
19. In vivo activity on murine tumors of a novel antitumor compound, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]phenazine-6-carboxamide sodium salt (NC-190).
Nakaike S; Yamagishi T; Samata K; Nishida K; Inazuki K; Ichihara T; Migita Y; Otomo S; Aihara H; Tsukagoshi S
Cancer Chemother Pharmacol; 1989; 23(3):135-9. PubMed ID: 2924370
[TBL] [Abstract][Full Text] [Related]
20. Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing.
Alkan SS; Rutschmann S; Grogg D; Erb P
Cell Immunol; 1993 Aug; 150(1):137-48. PubMed ID: 8102085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]